Received Feb 19, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
Malaise; Palpitations; This non-serious case was reported by a pharmacist via sales rep and described the occurrence of palpitation in a female patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 1st dose of Shingrix (unknown arm). On an unknown date, less than a day after receiving Shingrix, the patient experienced palpitation (Verbatim: Palpitations) and malaise (Verbatim: Malaise). The patient was treated with paracetamol (Tylenol) and ibuprofen. The outcome of the palpitation was resolved (duration 2 days) and the outcome of the malaise was not resolved. The reporter considered the palpitation and malaise to be related to Shingrix. The company considered the palpitation and malaise to be related to Shingrix. Additional Information: GSK Receipt date: 13-FEB-2026. The patient experienced palpitations on a regular basis during the day following vaccination. The patient did not receive any other vaccines on the day of vaccine administration. The patient also reported experiencing malaise that had lasted through the weekend, but they had expected this to happen. The patient had reported experiencing general malaise following the administration of the first dose of Shingrix. The batch number was not provided and a request for this information has been made.